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Abstract Despite elevated cathepsin L mRNA levels in kidney 
tumors, cathepsin L protein/activity was scarcely detectable in 
these tumors. As a possible reason, we detected two new splice 
variants of human cathepsin L mRNAs not identical to those 
previously reported. Besides the normal 'full-length' mRNA 
(hCATL-A) there is one form lacking 27 nucleotides (hCATL-A 
I) and another form lacking 90 nucleotides (hCATL-A II) in 
exon I. The splice variants do not influence the amino acid 
sequence of the translational product, hCATL-A and hCATL-A 
I probably form a secondary structure at the 5' non-coding 
sequence not present in hCATL-A II. 
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1. Introduction 
The lysosomal cysteine proteinase cathepsin L is found in 
most cells and tissues. The enzyme cleaves a wide spectrum of 
intra- and extracellular protein substrates [1]. Besides physio- 
logical effects, it may support processes like neovascularisa- 
tion, invasion and metastasis of tumor cells [24]. A high level 
of cathepsin L expression is detected in many tumors of lung, 
colon and breast [5]. High levels of cathepsin L mRNA have 
been observed in kidney tumor as well, although elevated 
cathepsin L protein and activity has not been determined in 
these cancers (Kirschke et al., unpublished results). Two var- 
iants of human cathepsin L mRNA have been reported [6,7]. 
Chauhan et al. [8] analyzed the genomic organization and 
chromosomal localization of these two forms named 
hCATL-A and hCATL-B. Both forms of human cathepsin 
L mRNAs are concurrently expressed in different cell lines. 
They are encoded by a single gene. HCATL-A  and hCATL-B 
mRNAs differ in the sequence of the non-coding exon I, 
therefore, the resulting proteins of the two mRNA forms 
are identical. Exon I of hCATL-A consists of 278 nucleotides, 
while exon I of hCATL-B consists of 181 nucleotides. The 
exons are not homologous: exon I of hCATL-B is identical 
to the 3' end of intron I of hCATL-A. Although the authors 
speculated about the different expression efficiency of both 
forms, they did not report on enzyme levels encoded by the 
two mRNA species. Here, we report two new splice variants 
of human cathepsin L, identified first in kidney tumor tissue, 
and show the distribution of these forms to be different in 
various tissues and cell lines. 
2. Materials and methods 
2.1. Tissues and cell cultures 
Tissue material was taken from nine patients uffering from kidney 
tumors. Immediately after the operation the material was divided into 
central tumor tissue, peripheral tumor tissue and normal tissue, 
checked by histological methods, and stored in liquid nitrogen until 
further use. 
Furthermore, we analyzed RNA of the lung carcinoma cell lines 
97TM1, 32M1 and 103H [10], of leukemia lymphoma cell lines Jurkat, 
Molt-4, Reh, K-562 [11] and of a normal human fibroblast cell line as 
a control. Cell lines were maintained in RPMI and 10% fetal bovine 
serum (Gibco-BRL). 
2.2. RNA isolation and cDNA synthesis 
Total RNA was isolated with Trizol (Gibco BRL) by a modified 
method of Chomczynski and Sacchi [12]. Isolated RNA was used for 
synthesis of cDNA, RT-PCR and Northern blotting. 2 ~tg of isolated 
total RNA were used for reverse transcription of mRNA into cDNA 
in a 10 ~tl assay with oligo(dT)12 l~ and M-MLV reverse transcriptase 
(Gibco BRL). 
2.3. cDNA amplification 
cDNA was amplified by PCR with specific human cathepsin L 
primers in exons I and IV and VIII. The following primers (name 
length, orientation, 5' position on target sequence in hCATL-A and 
sequence in the 5'-3' direction) were used: hCLls (19mer, sense, 142, 
CAG CCC TGG CAA CGA GAG C); hCL2s (20mer, sense, 267, 
GGG TGG ACA CAG GTT TTA AA); hCL2a (25mer, antisense, 
498, TTT CCC TTC CCT GTA TTC CTG ATT G); hCL4s (20mer, 
sense, 615, TCT GTT TTA TGA GGC CCC CA); hCL4a (20mer, 
antisense, 635, TGG GGG CGA GAT AAA ACA GA); hCL8a 
(19mer, antisense, 1334, TGC GCC ATC CCC AGT CAA G) synthe- 
sized by TIB MOLBIOL. 
Conditions for PCR were determined with the computer program 
Amplifier 2.0 (Labsoft). PCRs were carried out on a MaxiCycler PTC 
100 (MJ Research). 
2.4. Northern blot analysis 
10/ag of isolated total RNA were separated. Blots were prehybrid- 
ized at 42°C. Hybridization was performed with a [ot-32p]dCTP-la- 
beled 720 bp cathepsin L cDNA fragment and a 329 bp human ~- 
actin cDNA fragment, respectively, overnight at 42°C in 48% forma- 
mide, 10% dextran sulfate (Pharmacia LKB Biotechnology Inc.), 
4.SxSSC, 1 xDenhardt's olution, 10 mM Tris, pH 7.4, 100 ~g/ml 
salmon sperm DNA, 1% SDS, containing 0.8-1.5 x 10 6 cpm (~_32p)_ 
labeled DNA/ml. Filters were washed twice in 2 X SSC, 0.1% SDS at 
42°C for 10 min, and twice in 0.2X SSC and 0.1% SDS at 65°C for 30 
min each. Blots were analyzed with a phosphor imager (Biorad) after 
2 h exposure. 
2.5. DNA sequencing 
Sequencing of cDNA fragments were performed with IR labeled 
primers hCLls and hCL4a (synthesized by MWG Biotech) by cycle 
sequencing with Sequitherm sequencing kit (Epicentre) and analyzed 
on a Licor 4000 Sequencer (MWG Biotech). 
3. Results 
*Corresponding author. Fax: (49) (36 41) 63 12 89. 
3.1. Expression of  human cathepsin L 
We used total RNA of kidney tumor material as template 
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Fig. l. Structures of human cathepsin L mRNA. (a) 'Full-length' form hCATL-A with a 278 bp exon I (hatched area represents the region of 
alternative splicing). (b) Form hCATL-A I lacking 27 bp at the 3' end of exon I. (c) Form hCATL-A II lacking 90 bp at the 3' end of exon I. 
for cDNA synthesis by reverse transcription with oligo(dT). 
We expected a 1193 bp fragment after PCR amplification of 
the cDNA samples with the primer pair hCLls/hCL8a. It 
should code for the whole sequence of human cathepsin L
and should contain parts of the 5' and 3' untranslated re- 
gions. Instead, we detected three PCR products of mildly 
varying length. To analyze further the differences, we per- 
formed another PCR using the primer pair hCLls/hCL2a lo- 
cated in the 5' region of exon I and in the middle part of exon 
III, respectively. The resulting three forms exhibited the fol- 
lowing lengths: form hCATL-A is 357 bp, form hCATL-A I 
is 330 bp and form hCATL-A II is 267 bp long (Fig. 1). 
Furthermore, we studied whether these three forms were 
normal or tumor forms of hCATL-A. In order to answer 
this question we analyzed the total RNA of 4 different estab- 
lished cell lines of lung cancers and of normal human fibro- 
blasts. All cell lines studied showed the presence of hCATL-A, 
A I and AI I .  Since the three forms are amplified to different 
extents (Fig. 2), we addressed the question as to whether one 
of the variants is representative for the invasion front of a 
tumor. Therefore, we performed RT-PCR with total RNA 
as template isolated from tumor periphery and from normal 
renal tissue as control. As shown in Fig. 2, form hCATL-A II 
seems to be more highly concentrated in peripheral tumor 
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Fig. 2. Distribution of human cathepsin L mRNA splice variants in 
normal and cancerous renal tissue. Electrophoresis of the RT-PCR 
products of normal (n) and tumor periphery (tp) tissues from five 
patients (I V) with kidney tumor. The three bands in each lane 
were amplified with primer pair hCLls/hCL2a. They represent 
lengths of 357 bp (hCATL-A), 330 bp (hCATL-A I) and 267 bp 
(hCATL-A II). 
tissue than in normal tissue. The total hCATL mRNA was 
greater in peripheral tumor tissue than in normal tissue (10 ~tg 
of total RNA were used in every sample) as shown by a 
second hybridization with a human ~-actin probe. 
Although cathepsin L activity is noticeably high in normal 
kidney tissue, Kirschke et al. (unpublished) were unable to 
detect elevated cathepsin L levels in kidney carcinomas, more- 
over, cathepsin L was diminished in these tumors in compar- 
ison to normal kidney tissue as revealed by activity determi- 
nation and by ELISA as well. Similarly, some leukemia cells 
also do not show any cathepsin L activity (Kirschke, unpub- 
lished results). Therefore, we examined the human cathepsin L 
mRNA levels in some leukemia cell lines by Northern blot 
analysis. The 720 nucleotide probe was used. The T-cell leu- 
kemia cell lines did not show any signal with this probe (Fig. 
3). In all other samples ignals of only one band were detect- 
able because the resolution in this Northern blot analysis is 
not good enough to discriminate between hCATL-A, hCATL- 
A I and hCATL-A II. 
To confirm these results we performed RT-PCR of total 
RNA of these cell lines and tissues. Whereas the cell lines 
Reh and K-562 showed the same hCATL-A mRNA pattern 
as normal fibroblasts or kidney tissue the cell lines Jurkat and 
Molt-4 did not show any band of cathepsin L mRNA at all 
(Fig. 4). Jurkat and Molt-4 are cell lines of T-cell origin but 
Reh and K-562 are cell lines of B-cell origin. 
3.2. DNA sequencing 
By sequencing the PCR fragments using IR labeled primers 
hCLls and hCL4a we found the hCATL-A form described by 
Gal and Gottesman [7]. It is the largest form. In form 
hCATL-A I, 27 nucleotides at the 3' end of exon I are absent, 
and in form hCATL-A II, 90 nucleotides atthe 3' end of exon 
I are absent. 
3.3. Determination of potential splice sites 
The two additional forms (hCATL-A I and hCATL-A II) 
of human cathepsin L have not been found in any database. 
The nucleotides around the region of 27 and 90 bp upstream 
of the border between exon I and intron I are typical splice 
sites. Using the splice site prediction method of Solovyev et al. 
[13] we found the highest score for potential splicing at posi- 
tion 189 as occurring in form hCATL-A II lacking 90 nucleo- 
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Fig. 3. Analysis of different leukemia cell lines, human kidney tumor tissue and fibroblasts for the presence of human cathepsin L mRNA. 
(a) Northern blot of total RNA isolated from: 1, Jurkat; 2, Molt-4; 3, K-562; 4, Reh; 5, human fibroblast cell line hybridized with a human 
cathepsin L cDNA probe. 10 lag total RNA were loaded on each lane. (b) Electrophoretic patterns of RT-PCR products amplified from the 
same cell lines as in (a): 1, molecular weight marker; 2, Jurkat; 3, Molt-4; 4, K-562; 5, Reh; 6, human fibroblast cell line. The primer pair 
hCL2s/hCL8.1a was used. The amplified hCATL fragments correspond to 1021 bp. 
tides. Additionally, we determined putative exon-exon junc- 
tions of the cDNA of hCATL-A. We found such junctions in 
positions 251 and 188 corresponding to variants hCATL-A I 
and hCATL-A II. 
3.4. Calculation o f  secondary structure 
The secondary structures of the three splice variants were 
calculated using the method of Zuker and Stiegler [14] with 
the computer program RNAfold. Schematic representations 
of different calculated secondary structures of human cathep- 
sin L mRNA forms hCATL-A/A I/A II are shown in Fig. 
4a,b. The splice variants hCATL-A and hCATL-A I form a 
stem loop at identical sites of mRNA sequence in exon I 
(nucleotides 199 222). In contrast, variant hCATL-A II 
does not form a stem loop (Fig. 4c). The nucleotides of the 
stem loop site in form hCATL-A and hCATL-A I are absent 
in hCATL-A II due to alternative splicing. Such a stem loop 
can be a potential binding site of translational factors. 
4. Discussion 
In most malignant tumors the upregulation of the proteo- 
lyric capacity is positively correlated with a poor prognosis, 
i.e. with the extent of malignancy. Various proteases can con- 
tribute to this capacity, including urokinase type plasminogen 
activator (uPA), matrix metalloproteinases (MMP), cathepsin 
D and also the cysteine proteases cathepsins L and B [15]. The 
dramatic rise of cathepsin L mRNA in renal cancers [5] com- 
pared to normal kidney tissue suggested the overexpression f 
cathepsin L in these tumors as well. However, the opposite 
was the case as Kirschke et al. observed very recently (unpub- 
lished results): the cathepsin L level was lower in kidney tu- 
mors than in normal kidney tissue as shown on a protein 
basis. The explanation of this phenomenon, therefore, should 
be found at the translational level. 
The stem loop structure built by the hCATL-A and 
hCATL-A I obviously can bind to proteins regulating the 
translational efficiency. The 90 nucleotides present in 
hCATL-A and A I but absent in hCATL-A II are highly 
homologous (63.3%) to a G/C-rich region in the 5' non-cod- 
ing region of TGF-133 mRNA. The homologue part of the 
mRNA in TGF-131 was shown to form two stem loops re- 
sponsible for a post-transcriptional inhibition mechanism 
[16]. In the murine arylsulfatase A mRNA a similar sequence 
(73% homologous to hCATL-A and hCATL-A I sequences) 
was found at the 3' untranslated region probably as a trans- 
acting element [17]. Expression experiments are now in pro- 
gress to measure the translational efficiency of the three 
mRNA splice variants. 
Our results of variable transcripts in 5' untranslated region 
(UTR) of human cathepsin L show similarity to those re- 
ported by Berquin et al. [9] for human cathepsin B. They 
also found a trend toward preferential expression of one 
form (exon 2a) by tumors and speculated that stabilizing se- 
quences accumulated at a higher steady-state level. 
The striking result of the complete absence of cathepsin L 
mRNA in T cell derived leukemic ells raises the question as 
to the reason for this deletion. The genomic locus of human 
cathepsin L is on chromosome 9q22.1-q22.2. This is very close 
to the locus of the growth arrest-specific gene 1 (GAS1) which 
has been mapped to 9q21.3-q22.1. GAS1 suppresses DNA 
synthesis, and has been detected in myeloid malignancies 
[18]. It is a tumor suppressor gene. The absence of cathepsin 
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Fig. 4. Calculation of secondary structures of the 3 splice variants 
of human cathepsin L according to the computer program RNA- 
fold. (a) hCATL-A with a stem loop at nucleotides 199-222 marked 
by an arrow; (b) hCATL-A I lacking 27 nucleotides, but still form- 
ing a stem loop at the same position as in form hCATL-A; 
(c) hCATL-A II lacking 90 nucleotides without a stem loop. 
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L in some malignant myeloid cell lines, therefore, may rather 
be a consequence of the fatal GAS1 deletion combined with a 
cathepsin L deletion than a per se event. In malignant tumors 
of the myeloid system, proteases obviously play a minor role 
in the control of growth and metastasis as compared to that in 
solid tumors. 
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